vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Red Cat Holdings, Inc. (RCAT). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $9.6M, roughly 1.1× Red Cat Holdings, Inc.). Red Cat Holdings, Inc. runs the higher net margin — -166.0% vs -186.0%, a 19.9% gap on every dollar of revenue. On growth, Red Cat Holdings, Inc. posted the faster year-over-year revenue change (988.2% vs 112.8%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Mega Cat Studios is an American video game development and publishing company located in Pittsburgh, Pennsylvania. It was founded in 2015 by James Deighan, Nick Mann, and Zack Manko.

CCCC vs RCAT — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.1× larger
CCCC
$11.0M
$9.6M
RCAT
Growing faster (revenue YoY)
RCAT
RCAT
+875.4% gap
RCAT
988.2%
112.8%
CCCC
Higher net margin
RCAT
RCAT
19.9% more per $
RCAT
-166.0%
-186.0%
CCCC

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CCCC
CCCC
RCAT
RCAT
Revenue
$11.0M
$9.6M
Net Profit
$-20.5M
$-16.0M
Gross Margin
6.6%
Operating Margin
-210.1%
-181.7%
Net Margin
-186.0%
-166.0%
Revenue YoY
112.8%
988.2%
Net Profit YoY
40.7%
-29.0%
EPS (diluted)
$-0.09
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
RCAT
RCAT
Q4 25
$11.0M
Q3 25
$11.2M
$9.6M
Q2 25
$6.5M
Q1 25
$7.2M
$1.6M
Q4 24
$5.2M
$0
Q3 24
$15.4M
Q2 24
$12.0M
Q1 24
$3.0M
$5.8M
Net Profit
CCCC
CCCC
RCAT
RCAT
Q4 25
$-20.5M
Q3 25
$-32.2M
$-16.0M
Q2 25
$-26.0M
Q1 25
$-26.3M
$-23.1M
Q4 24
$-34.6M
$-13.3M
Q3 24
$-24.7M
Q2 24
$-17.7M
Q1 24
$-28.4M
$-5.5M
Gross Margin
CCCC
CCCC
RCAT
RCAT
Q4 25
Q3 25
6.6%
Q2 25
Q1 25
-52.2%
Q4 24
Q3 24
Q2 24
Q1 24
18.8%
Operating Margin
CCCC
CCCC
RCAT
RCAT
Q4 25
-210.1%
Q3 25
-306.4%
-181.7%
Q2 25
-441.0%
Q1 25
-402.9%
-765.7%
Q4 24
-728.4%
Q3 24
-183.9%
Q2 24
-178.6%
Q1 24
-1060.2%
-76.0%
Net Margin
CCCC
CCCC
RCAT
RCAT
Q4 25
-186.0%
Q3 25
-286.4%
-166.0%
Q2 25
-402.6%
Q1 25
-363.7%
-1418.9%
Q4 24
-667.8%
Q3 24
-160.6%
Q2 24
-147.6%
Q1 24
-933.2%
-93.9%
EPS (diluted)
CCCC
CCCC
RCAT
RCAT
Q4 25
$-0.09
Q3 25
$-0.44
$-0.16
Q2 25
$-0.37
Q1 25
$-0.37
$-0.27
Q4 24
$-0.50
Q3 24
$-0.35
Q2 24
$-0.26
Q1 24
$-0.41

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
RCAT
RCAT
Cash + ST InvestmentsLiquidity on hand
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$253.3M
Total Assets
$359.1M
$286.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
RCAT
RCAT
Q4 25
$74.6M
Q3 25
$58.8M
Q2 25
$78.2M
Q1 25
$51.3M
Q4 24
$55.5M
Q3 24
$59.6M
Q2 24
$73.1M
Q1 24
$89.7M
Stockholders' Equity
CCCC
CCCC
RCAT
RCAT
Q4 25
$256.6M
Q3 25
$154.4M
$253.3M
Q2 25
$174.1M
Q1 25
$195.1M
$28.9M
Q4 24
$216.0M
$27.0M
Q3 24
$242.7M
Q2 24
$247.1M
Q1 24
$258.3M
$49.6M
Total Assets
CCCC
CCCC
RCAT
RCAT
Q4 25
$359.1M
Q3 25
$265.5M
$286.0M
Q2 25
$296.5M
Q1 25
$319.5M
$59.7M
Q4 24
$349.6M
$51.1M
Q3 24
$376.1M
Q2 24
$381.1M
Q1 24
$398.4M
$55.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
RCAT
RCAT
Operating Cash FlowLast quarter
$-22.1M
$-23.9M
Free Cash FlowOCF − Capex
$-24.5M
FCF MarginFCF / Revenue
-254.2%
Capex IntensityCapex / Revenue
6.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-55.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
RCAT
RCAT
Q4 25
$-22.1M
Q3 25
$-31.2M
$-23.9M
Q2 25
$-12.1M
Q1 25
$-33.3M
$-15.9M
Q4 24
$-17.9M
$-10.1M
Q3 24
$-24.1M
Q2 24
$-5.0M
Q1 24
$-18.1M
$-4.1M
Free Cash Flow
CCCC
CCCC
RCAT
RCAT
Q4 25
Q3 25
$-31.6M
$-24.5M
Q2 25
Q1 25
$-16.2M
Q4 24
$-17.9M
$-10.2M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
$-4.2M
FCF Margin
CCCC
CCCC
RCAT
RCAT
Q4 25
Q3 25
-281.5%
-254.2%
Q2 25
Q1 25
-992.9%
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
-71.1%
Capex Intensity
CCCC
CCCC
RCAT
RCAT
Q4 25
Q3 25
3.7%
6.9%
Q2 25
Q1 25
16.8%
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%
0.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCCC
CCCC

Segment breakdown not available.

RCAT
RCAT

Products$8.5M88%
Services$1.2M12%

Related Comparisons